If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Adjunctive Screening Device to Enhance Early Detection of Breast Disease CRANFORD, N.J., Oct. 28, 1996 -- During Breast Cancer Awareness Month, HumaScan, Inc. (Nasdaq: HMSC), a high-tech company that develops products for early disease detection, is releasing information on its proprietary device that can indicate the possibility of heat emitting, medically significant breast disease, including cancer. It will be available to physicians mid-1997. The device, a non-invasive, fifteen-minute test, may provide a new, cost-effective adjunct to physical clinical examination at doctors' offices and improve chances for detection of fast growing tumors in the intervals between mamographic screening or when mammography is not indicated by screening guidelines for women under 50," says Richard Luciani, M.D., FACOG, a gynecologist who is the company's medical advisor. He explains that when early stage cancer or certain forms of breast disease are present, cellular activity increases, producing heat. This product records skin temperatures on each breast, with a temperature difference of two degrees Fahrenheit or more between breasts alerting the physician to possible underlying breast disease in need of further examination. "Because of its value to women of all ages, the device may become an integral part of women's routine physical exams," adds Dr. Luciani. "We are hoping that this product will become to breast disease what PAP smear has become to cervical disease." Women who do not undergo routine mamograms and women known to be at risk may still be particularly susceptible to fast-growing cancers. Dr. Luciani also points out that many women, with dense breast tissue, can benefit from the information that this test method provides at the time of annual or more frequent office examination. HumaScan, Inc. president and CEO, Donald Brounstein, asserts, "It is widely recognized that early detection of breast cancer saves lives. More than 90 percent of women diagnosed with early stage, localized breast cancer are alive five years later, yet, only 58 percent of cancers are diagnosed at this stage." He adds that during a clinical examination, a physician must rely on fingers (or palpation) and eyesight to detect tumors in the breast, which may often occur when cancer is no longer localized or confined to the breast. "This new device and test method can provide an earlier adjunctive alert before possible referral to mammography." The device is sensitive, inexpensive and disposable, complementing current screening methods; such as breast self-examination, clinical examination by a physician, as well as mammography. It alerts primary care physicians and specialists to possible breast pathology, and is a totally objective, adjunctive test, which is easy to use, with instant readings while the woman is in the exam room for her physical examination. The product will be available to all physicians, including gynecologists, internal medicine, family practice and others, by mid-1997. This release contains forward-looking information including statements regarding the positive impact that this adjunctive product may have in assisting physicians in early detection of breast disease in women of all ages. Additional information on factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission. Headquartered at 125 Moen Avenue, Cranford, New Jersey 07016 with nationwide distribution capabilities, HumaScan, Inc. is a company that focuses on easy to use, low cost products and devices that assist various physicians and specialists in diagnosis and early detection of disease.
|
